Analysts See $-0.25 EPS for Spectrum Pharmaceuticals, Inc. (SPPI)

February 15, 2018 - By Winifred Garcia

 Analysts See $ 0.25 EPS for Spectrum Pharmaceuticals, Inc. (SPPI)
Investors sentiment increased to 2.84 in 2017 Q3. Its up 1.89, from 0.95 in 2017Q2. It is positive, as 13 investors sold Spectrum Pharmaceuticals, Inc. shares while 19 reduced holdings. 38 funds opened positions while 53 raised stakes. 71.60 million shares or 29.39% more from 55.33 million shares in 2017Q2 were reported.
Invesco invested in 393,459 shares or 0% of the stock. 3,788 are owned by Envestnet Asset Mngmt Inc. Moreover, Product Ptnrs Ltd Liability Co has 0.07% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Sei holds 818 shares or 0% of its portfolio. California Pub Employees Retirement Systems reported 155,700 shares stake. Teachers Retirement Systems Of The State Of Kentucky has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Mason Street Advsrs Ltd Liability Corp holds 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 19,261 shares. Public Sector Pension Inv Board accumulated 47,076 shares or 0% of the stock. Pillar Pacific Mgmt Limited Liability Com holds 0.03% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 18,500 shares. Pinebridge Investments L P reported 123,826 shares. 10,412 were reported by Amalgamated Fincl Bank. Blackrock reported 11.98M shares stake. Tower Lc (Trc) invested in 866 shares. M&T Bankshares Corp stated it has 45,258 shares or 0% of all its holdings. Wells Fargo And Mn has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).

Analysts expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report $-0.25 EPS on March, 14.They anticipate $0.03 EPS change or 13.64 % from last quarter’s $-0.22 EPS. After having $-0.22 EPS previously, Spectrum Pharmaceuticals, Inc.’s analysts see 13.64 % EPS growth. The stock increased 1.55% or $0.33 during the last trading session, reaching $21.61. About 405,645 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 20.03% since February 15, 2017 and is downtrending. It has underperformed by 36.73% the S&P500.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma had 11 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained the shares of SPPI in report on Monday, October 9 with “Buy” rating. Jefferies maintained it with “Buy” rating and $9.0 target in Thursday, August 24 report. H.C. Wainwright reinitiated the stock with “Buy” rating in Wednesday, August 16 report. The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) earned “Hold” rating by Zacks on Thursday, August 27. As per Friday, August 7, the company rating was maintained by RBC Capital Markets. The firm has “Buy” rating given on Wednesday, June 7 by Jefferies. The stock has “Buy” rating by Jefferies on Friday, February 10. The rating was maintained by RBC Capital Markets on Thursday, November 5 with “Outperform”.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $2.15 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

More notable recent Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news were published by: Seekingalpha.com which released: “Spectrum Pharmaceuticals: What The Positive ADVANCE Study Entails?” on February 07, 2018, also Seekingalpha.com with their article: “Spectrum Pharmaceuticals: What Does The Recent Management Streamlining Signify?” published on February 07, 2018, Businesswire.com published: “Spectrum Pharmaceuticals to Present Corporate Update at the Noble Capital …” on January 23, 2018. More interesting news about Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) were released by: Nasdaq.com and their article: “Spectrum Pharmaceuticals Up 134% in 6 Months: Here’s Why” published on January 19, 2018 as well as Zacks.com‘s news article titled: “Spectrum Pharma’s Rolontis Positive in Pivotal Cancer Study” with publication date: February 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.